^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    JNJ-8343

    i
    Other names: JNJ-8343, JNJ-78278343, JNJ78278343, JNJ8343, JNJ 78278343, JNJ 8343
    Associations

    News

    Trials
    Company:
    J&J, Zymeworks
    Drug class:
    CD3 agonist, KLK2 inhibitor
    Related drugs:
    Associations

    News

    Trials
    1m
    A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P1, N=200, Recruiting, Janssen Research & Development, LLC | N=345 --> 200
    Enrollment change
    |
    docetaxel • Xtandi (enzalutamide capsule) • abiraterone acetate • prednisone • Nubeqa (darolutamide) • cabazitaxel • Erleada (apalutamide) • cetrelimab (JNJ-63723283) • JNJ-8343
    4ms
    A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer (clinicaltrials.gov)
    P1, N=260, Recruiting, Janssen Research & Development, LLC | Trial completion date: Nov 2025 --> Feb 2026
    Trial completion date • Metastases
    |
    JNJ-8343
    5ms
    A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer (clinicaltrials.gov)
    P1, N=260, Recruiting, Janssen Research & Development, LLC | N=165 --> 260
    Enrollment change • Metastases
    |
    JNJ-8343
    6ms
    A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P1, N=345, Recruiting, Janssen Research & Development, LLC | Trial completion date: Mar 2026 --> Sep 2027
    Trial completion date
    |
    docetaxel • Xtandi (enzalutamide capsule) • abiraterone acetate • prednisone • Nubeqa (darolutamide) • cabazitaxel • Erleada (apalutamide) • cetrelimab (JNJ-63723283) • JNJ-8343
    6ms
    A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P1, N=345, Recruiting, Janssen Research & Development, LLC | N=20 --> 345
    Enrollment change • Combination therapy • Metastases
    |
    docetaxel • Xtandi (enzalutamide capsule) • abiraterone acetate • prednisone • Nubeqa (darolutamide) • cabazitaxel • Erleada (apalutamide) • cetrelimab (JNJ-63723283) • JNJ-8343
    11ms
    A Study of JNJ-78278343 in Combination With JNJ-63723283 (Cetrelimab) for Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P1, N=20, Recruiting, Janssen Research & Development, LLC | Phase classification: P1b --> P1
    Phase classification • Combination therapy • Metastases
    |
    cetrelimab (JNJ-63723283) • JNJ-8343
    1year
    A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer (clinicaltrials.gov)
    P1, N=165, Recruiting, Janssen Research & Development, LLC | Trial completion date: Nov 2024 --> Nov 2025
    Trial completion date • Metastases
    |
    JNJ-8343
    1year
    A Study of JNJ-87189401 Plus JNJ-78278343 for Advanced Prostate Cancer (clinicaltrials.gov)
    P1, N=110, Recruiting, Janssen Research & Development, LLC | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    JNJ-8343
    1year
    A Study of JNJ-87189401 Plus JNJ-78278343 for Advanced Prostate Cancer (clinicaltrials.gov)
    P1, N=110, Not yet recruiting, Janssen Research & Development, LLC
    New P1 trial • Metastases
    |
    JNJ-8343
    over1year
    A Study of JNJ-78278343 in Combination With JNJ-63723283 (Cetrelimab) for Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P1b, N=20, Recruiting, Janssen Research & Development, LLC | Not yet recruiting --> Recruiting | N=40 --> 20
    Enrollment open • Enrollment change
    |
    cetrelimab (JNJ-63723283) • JNJ-8343